ScripInvestors are acutely focused on the loss of exclusivity (LOE) of Merck & Co.’s mega-blockbuster Keytruda (pembrolizumab) in 2028, but head of global clinical development and chief medical officer
ScripAkeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke
Generics BulletinFresenius Kabi is set to enjoy a 14-year jump on the US patents shielding Pacira BioSciences’ Exparel (bupivacaine) liposomal injectable, albeit with a volume limit that will last for nearly a decade,
Pink SheetDespite the ongoing upheaval across the agency, the US Food and Drug Administration maintained its typical reliability when it came to meeting user fee goal dates in the first quarter of 2025, the Pi